Imdelltra, a bispecific T cell engager, is FDA approved for extensive-stage small cell lung cancer after platinum-based chemotherapy, providing a novel immunotherapy treatment option.
Small cell lung cancer (SCLC) is aggressive with a 3% five-year survival rate for extensive-stage. Imdelltra targets DLL3 protein, administered via intravenous infusion every two weeks.
FDA approval for Imdelltra came early based on Phase 2 trial results in over 200 SCLC patients. The drug activates T cells to simultaneously attack cancer cells, offering hope for those unresponsive to previous therapies.
[
add
]
[
|
|
...
]